The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases

1Naga Chalasani, MD, FAASLD; 2Zobair Younossi, MD, FAASLD; 3Joel E. Lavine, MD, PhD, FAASLD; 4Michael Charlton, MD, FAASLD; 5Kenneth Cusi, MD, FAASLD; 6Mary Rinella, MD, FAASLD; 7Stephen A. Harrison, MD, FAASLD; 8Elizabeth M. Brunt, MD, FAASLD; 9Arun J. Sanyal, MD, FAASLD

1Indiana University School of Medicine, Indianapolis, IN; 2Center for Liver Disease and Department of Medicine, Inova Fairfax Hospital, Falls Church; 3Columbia University, New York, NY; 4University of Chicago, Chicago, IL; 5University of Florida, Gainesville, FL; 6Northwestern University, Chicago, IL; 7Pinnacle Clinical Research, San Antonio, TX; 8Washington University School of Medicine, St. Louis, MO; 9Virginia Commonwealth University, Richmond, VA

Author for Correspondence

Naga Chalasani, MD, FAASLD
Indiana University School of Medicine
702 Rotary Circle, Suite 225
Indianapolis, IN 46202
Fax (317) 278-1949
E-mail: nchalasa@iu.edu
Abbreviations

NAFLD: Nonalcoholic Fatty Liver Disease
NAFL: Nonalcoholic Fatty Liver
NASH: Nonalcoholic Steatohepatitis
T2DM: Type 2 Diabetes Mellitus
AST: Aspartate Aminotransferase
ALT: Alanine Aminotransferase
RCT: Randomized Controlled Trial
TONIC: Treatment of Nonalcoholic Fatty Liver Disease in Children
NAS: NAFLD Activity Score
MR: Magnetic Resonance
MRE: MR Elastography
VCTE: Vibration Controlled Transient Elastography
FUNDING

The funding for the development of this Practice Guidance was provided by the American Association for the Study of Liver Diseases.

AASLD APPROVAL

This practice guidance was approved by the American Association for the Study of Liver Diseases on June 15, 2017.

Acknowledgments

This Practice Guidance was developed under the direction of the AASLD Practice Guidelines Committee, which approved the scope of the guidance and provided the peer review. Members of the Committee include Tram T. Tran, MD, FAASLD (Chair), Michael W. Fried, MD, FAASLD (Board Liaison), Jawad Ahmad, MD, FAASLD, Joseph Ahn, MD, Alfred Sidney Barritt IV, MD, MSCR, James R Burton, Jr., MD, Udeme Ekong, MD, Fredric Gordon, MD, FAASLD, Simon P. Horslen, MD, George Ioannou, MD, FAASLD, Whitney E. Jackson, MD, Patrick S Kamath, MD, Fasiha Kanwal, MD, MSHS, David G Koch, MD, Michael D. Leise, MD, Jacqueline G. O’Leary, MD, Raphael B. Merriman, MD, FACP, FRCPI, (Immediate Past Chair) Michael L. Schilsky, MD, FAASLD, Amit G. Singal, MD, (Vice-Chair), James R. Spivey, MD, Helen S. Te, MD, FAASLD, and Michael Volk, MD. Dr. Merriman served as primary reviewer for the AASLD Practice Guidelines Committee and declared no conflicts of interest. As this guidance document is an update of the previous AASLD Practice Guideline published in 2012, there will be inevitable similarities in the text between the two documents. Authors thank Ms. Megan Comerford from Indiana University for her editorial assistance.
Preamble

This guidance provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care. A “Guidance” document is different from a “Guideline.” Guidelines are developed by a multidisciplinary panel of experts and rate the quality (level) of the evidence and the strength of each recommendation using the Grading of Recommendations, Assessment Development, and Evaluation (GRADE) system. A guidance document is developed by a panel of experts in the topic, and guidance statements, not recommendations, are put forward to help clinicians understand and implement the most recent evidence.

This Practice Guidance was commissioned by the American Association for the Study of Liver Diseases (AASLD) and is an update to the Practice Guideline published in 2012 in conjunction with the American Gastroenterology Association and the American College of Gastroenterology (1). Sections where there have been no notable newer publications are not modified, so some paragraphs remain unchanged. This narrative review and guidance statements are based on the following: (1) a formal review and analysis of the recently published world literature on the topic (Medline search up to August 2016); (2) the American College of Physicians’ Manual for Assessing Health Practices and Designing Practice Guidelines (2); (3) guideline policies of the AASLD; and (4) the experience of the authors and independent reviewers with regards to NAFLD.

This practice guidance is intended for use by physicians and other health professionals. As clinically appropriate, guidance statements should be tailored for individual patients. Specific guidance statements are evidence-based whenever possible, and, when such evidence is not

AASLD approved version submitted to Hepatology on June 28, 2017

Hepatology

This article is protected by copyright. All rights reserved.
available or is inconsistent, guidance statements are made based on the consensus opinion of the authors (3). This is a practice guidance for clinicians rather than a review article, and interested readers can refer to several recent comprehensive reviews (4-9). As this guidance document is lengthy, to make it easier for the reader a list of all guidance statements and recommendations are provided in a tabular form as Supplemental Table 1.

Definitions

For defining nonalcoholic fatty liver disease (NAFLD), there must be (a) evidence of hepatic steatosis, either by imaging or histology, and (b) lack of secondary causes of hepatic fat accumulation such as significant alcohol consumption, long-term use of a steatogenic medication, or monogenic hereditary disorders (Table 1). In the majority of patients, NAFLD is commonly associated with metabolic comorbidities such as obesity, diabetes mellitus, and dyslipidemia. NAFLD can be categorized histologically into nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH) (Table 2). NAFL is defined as the presence of ≥5% hepatic steatosis without evidence of hepatocellular injury in the form of hepatocyte ballooning. NASH is defined as the presence of ≥5% hepatic steatosis and inflammation with hepatocyte injury (eg, ballooning), with or without any fibrosis. For defining “advanced” fibrosis, this guidance document will be referring specifically to stages 3 or 4, ie, bridging fibrosis or cirrhosis.

Incidence and Prevalence of NAFLD in the General Population

Incidence of NAFLD:
There is a paucity of data regarding the incidence of NAFLD in the general population. A few studies have reported incidence of NAFLD from Asian countries, which are briefly summarized below:

- In a study that followed 11,448 subjects for 5 years, the incidence of NAFLD documented by ultrasound was 12% ($n = 1,418$) (10).
- In a study of 635 Nagasaki atomic bomb survivors who were followed for 11.6 years, the incidence of NAFLD documented by ultrasound was 19.9 per 1,000 person-years (11).
- In 565 subjects, the incidence of NAFLD at 3 to 5 years, diagnosed using magnetic resonance imaging and transient elastography, was estimated to be 13.5% (34 per 1,000 person-years) (12).
- In a cohort study, 77,425 subjects free of NAFLD at baseline were followed for an average of 4.5 years. During 348,193.5 person-years of follow-up, 10,340 participants developed NAFLD documented by ultrasound, translating to an incidence rate of 29.7 per 1,000 person-years (13).

The incidence rates for NAFLD in the general population of Western countries are even less commonly reported:

- A study from England using ICD-10 codes reported an incidence rate for NAFLD of 29 per 100,000 person-years. Given the inaccuracy of administrative coding such as ICD-10, this study most likely underestimates the true incidence of NAFLD (14).
- A study from Israel reported an incidence rate of 28 per 1,000 person-years (15).
- A recent meta-analysis estimated that the pooled regional incidence of NAFLD from Asia to be 52.34 per 1,000 person-years (95% confidence interval [CI]: 28.31-96.77) while the
incidence rate from the West is estimated to be around 28 per 1,000 person-years (95% CI: 19.34-40.57) (16).

Prevalence of NAFLD:

In contrast to the incidence data, there is a significantly higher number of publications describing the prevalence of NAFLD in the general population. These studies are summarized in a recent meta-analysis of the epidemiology of NAFLD:

- The meta-analysis estimated that the overall global prevalence of NAFLD diagnosed by imaging is around 25.24% (95% CI: 22.10-28.65%) (16).
- The highest prevalence of NAFLD is reported from the Middle East (31.79% [95% CI:13.48-58.23]) and South America (30.45% [95% CI: 22.74-39.440]) while the lowest prevalence rate is reported from Africa (13.48% [5.69-28.69]).(16)

As described elsewhere, the gold standard for diagnosing NASH remains a liver biopsy. Given that liver biopsy is not feasible in studies of the general population, there is no direct assessment of the incidence or prevalence of NASH. Nevertheless, there have been some attempts to estimate the prevalence of NASH by indirect means (16,17). The data regarding the prevalence of NASH in the general population are summarized in the following paragraphs:

- The prevalence of NASH among NAFLD patients who had liver biopsy for a “clinical indication” is estimated to be 59.10% (95% CI: 47.55-69.73) (16).
- The prevalence of NASH among NAFLD patients who had liver biopsy without a specific “clinical indication” (random biopsy for living-related donors etc.) is estimated from 6.67% (95% CI:2.17-18.73) to 29.85% (95% CI: 22.72-38.12) (16).
Given these estimates, one estimates that the prevalence of NASH in the general population ranges between 1.5% and 6.45% (16).

Prevalence of NAFLD in High-Risk Groups (Table 3)

Features of metabolic syndrome are not only highly prevalent in patients with NAFLD, but components of metabolic syndrome also increase the risk of developing NAFLD (16,18-20). This bidirectional association between NAFLD and components of metabolic syndrome has been strongly established. In this context, Table 3 provides a list of the established conditions (obesity, type 2 diabetes, hypertension, dyslipidemia) and emerging conditions (sleep apnea, colorectal cancer, osteoporosis, psoriasis, endocrinopathies, and polycystic ovary syndrome independent of obesity) that are associated with NAFLD (21,22).

- Obesity (excessive body mass index [BMI] and visceral obesity) is the most common and well documented risk factor for NAFLD. In fact, the entire spectrum of obesity, ranging from overweight to obese and severely obese, is associated with NAFLD. In this context, the majority (>95%) of patients with severe obesity undergoing bariatric surgery will have NAFLD (23,24).

- Type 2 diabetes mellitus (T2DM): There is a very high prevalence of NAFLD in individuals with T2DM. In fact, some studies have suggested that about a third to two-thirds of diabetic patients have NAFLD (18,25-27). It is also important to remember the importance of bidirectional association between NAFLD and T2DM. In this context, T2DM and NAFLD can develop almost simultaneously in a patient, which confounds the prevalence of NAFLD in patients with T2DM or the prevalence of T2DM in patients with
NAFLD. Nevertheless, this association and its bidirectional causal relationship require additional investigation.(28)

- Dyslipidemia: High serum triglyceride levels and low serum high-density lipoprotein (HDL) levels are also common in patients with NAFLD. The prevalence of NAFLD in individuals with dyslipidemia attending lipid clinics has been estimated to be 50% (29,30). In a large, cross-sectional study conducted among 44,767 Taiwanese patients who attended a single clinic, the enrollees were stratified into 4 subgroups based on their total cholesterol to HDL-cholesterol and triglyceride to HDL-cholesterol ratios. The overall prevalence rate of NAFLD was 53.76%; however, the NAFLD prevalence rate for those with the lowest total cholesterol to HDL-cholesterol and triglyceride to HDL-cholesterol ratios was 33.41%, whereas the prevalence rate in the group with the highest ratios was 78.04%.

- Age, gender, and ethnicity: The prevalence of NAFLD may vary according to age, gender, and ethnicity (31-39). In fact, both the prevalence of NAFLD and the stage of liver disease appear to increase with age (34-37).

Although controversial, male gender has been considered a risk factor for NAFLD. Furthermore, the prevalence of NAFLD in men is 2 times higher than in women (33,34,38).

The issues of ethnicity and its impact on NAFLD have evolved over the years. In fact, initial reports suggested that compared to non-Hispanic whites, Hispanic individuals have a significantly higher prevalence of NAFLD, whereas non-Hispanic blacks have a significantly lower prevalence of NAFLD (39). Although the prevalence of NAFLD among American-
Indian and Alaskan-Native populations seem to be lower (0.6% to 2.2%), these rates need to be confirmed (31,32). It is intriguing that most of the recent data suggest the ethnic differences reported for NAFLD may be explained by the genetic variation related to the PNPLA-3 gene (40).

In summary, the incidence of NAFLD varies across the world, ranging from 28.01 per 1,000 person-year (95% CI: 19.34-40.57) to 52.34 per 1,000 person-years (95% CI: 28.31-96.77).

Natural History and Outcomes of Nonalcoholic Fatty Liver Disease

Over the past 2 decades, studies have reported the natural history of patients with NAFLD (1,19,41-52). There is growing evidence that patients with histologic NASH, especially those with some degree of fibrosis, are at higher risk for adverse outcomes such as cirrhosis and liver-related mortality (1,18,19,41-52). These studies have also shown the following:

• Patients with NAFLD have increased overall mortality compared to matched control populations without NAFLD (53,54).

• The most common cause of death in patients with NAFLD is cardiovascular disease, independent of other metabolic comorbidities.

• Although liver-related mortality is the 12th leading cause of death in the general population, it is the second or third cause of death among patients with NAFLD (55).

• Cancer-related mortality is among the top 3 causes of death in subjects with NAFLD (55).

• Patients with histologic NASH have an increased liver-related mortality rate (56,57).

• In a recent meta-analysis, liver-specific and overall mortality rates among NAFLD and NASH were determined to be 0.77 per 1,000 (range, 0.33-1.77) and 11.77 per 1,000 person-
years (range, 7.10-19.53) and 15.44 per 1,000 (range, 11.72-20.34) and 25.56 per 1,000 person-years (range, 6.29-103.80), respectively (16).

- The incidence risk ratios for liver-specific and overall mortality for NAFLD were also determined to be 1.94 (range, 1.28-2.92) and 1.05 (range, 0.70-1.56), respectively (16).
- The most important histologic feature of NAFLD associated with long term mortality is fibrosis; specifically, zone 3 sinusoidal fibrosis plus periportal fibrosis (stage 2) to advanced (bridging fibrosis [stage 3] or cirrhosis [stage 4]). These are independently predictive of liver-related mortality (44,58,59).

- NAFLD is now considered the third most common cause of hepatocellular carcinoma (HCC) in the United States, likely due to the enormous number of patients with the condition (60). Given the growing epidemic of obesity, the incidence of NAFLD-related HCC has been shown to increase at a 9% annual rate (61).
- Patients with NAFLD-related HCC are older, have a shorter survival time, more often have heart disease, and are more likely to die from their primary liver cancer than other HCC patients (60).
- About 13% of HCC reported from a study of patients from Veteran Administration did not have cirrhosis. Among other factors, having NAFLD was independently associated with HCC in the absence of cirrhosis. This study confirms prior small reports of HCC in NAFLD patients without cirrhosis (62).
- It is important to recognize that most patients with cryptogenic cirrhosis may have what is considered “burned out” NAFLD (63). This particular group of patients with cryptogenic cirrhosis have a disproportionately high prevalence of metabolic risk factors (T2DM, obesity, metabolic syndrome) that resemble patients with NAFLD, but the pathologic assessment
seldom reports histological features consistent with NASH or even steatosis in the presence of cirrhosis (63,64).

**Important Outcomes in Patients with NAFLD**

One of the important surrogates for advanced liver disease is documentation of progressive hepatic fibrosis. In the recent meta-analysis, hepatic fibrosis progression in patients with histological NASH at baseline showed a mean annual fibrosis progression rate of 0.09 (95% CI: 0.06-0.12) (16). Several studies investigated the natural history of NASH cirrhosis in comparison to patients with hepatitis C cirrhosis (9,65,66). One large, prospective, US-based study observed a lower rate of decompensation and mortality in patients with NASH cirrhosis as compared to patients with hepatitis C cirrhosis (65). However, a more recent international study of 247 NAFLD patients with advanced fibrosis (bridging fibrosis and cirrhosis) followed over a mean duration of 85.6 ± 54.5 months showed an overall 10-year survival of 81.5%—a survival rate not different from matched patients with hepatitis C cirrhosis (1). This is confirmed with increasing numbers of patients with NAFLD presenting with HCC or requiring liver transplantation. In fact, NASH is now ranked as the second most common cause of liver transplantation and will likely overtake hepatitis as the number one cause of liver transplantation in the future, as more hepatitis C virus patients are treated with highly curative antiviral regimens (9,67).

As noted previously, another important, long-term outcome of liver disease is the development of HCC. The current HCC incidence rate among NAFLD patients was determined to be 0.44 (range: 0.29-0.66) per 1,000 person-years (16). In another study of patients with HCC, 54.9% of
the HCC cases were related to hepatitis C virus, 16.4% to alcoholic liver disease, 14.1% were related to NAFLD, and 9.5% to hepatitis B virus. However, it is estimated that the risk for developing HCC in noncirrhotic NAFLD patients is very small given the extremely large number of patients with noncirrhotic NAFLD within the general population (61).

**Alcohol Consumption and Definition of NAFLD**

By definition, NAFLD indicates the lack of evidence for ongoing or recent consumption of significant amounts of alcohol. However, the precise definition of significant alcohol consumption in patients with suspected NAFLD is uncertain. A consensus meeting recommended that, for NASH clinical trials candidate eligibility purposes, significant alcohol consumption be defined as >21 standard drinks per week in men and >14 standard drinks per week in women over a 2-year period prior to baseline liver histology (68). According to the National Institute on Alcohol Abuse and Alcoholism, a standard alcoholic drink is any drink that contains about 14 g of pure alcohol (69). Unfortunately, the definition of significant alcohol consumption in published NAFLD literature has been inconsistent (70).

**Guidance Statement**

1. **Ongoing or recent alcohol consumption > 21 standard drinks on average per week in men and > 14 standard drinks on average per week in women is a reasonable threshold for significant alcohol consumption when evaluating patients with suspected NAFLD.**

**Evaluation of Incidentally Discovered Hepatic Steatosis**

Some patients undergoing thoracic and abdominal imaging for reasons other than liver symptoms, signs, or abnormal biochemistry may demonstrate unsuspected hepatic steatosis. A
recent study showed that 11% of patients with incidentally discovered hepatic steatosis may be at high risk for advanced hepatic fibrosis based on the calculated NAFLD Fibrosis Score (71). However, the natural history and optimal diagnostic and management strategies for this patient population have not been investigated.

**Guidance Statements**

2. **Patients with unsuspected hepatic steatosis detected on imaging who have symptoms or signs attributable to liver disease or have abnormal liver chemistries should be evaluated as though they have suspected NAFLD and worked up accordingly.**

3. **Patients with incidental hepatic steatosis detected on imaging who lack any liver-related symptoms or signs and have normal liver biochemistries should be assessed for metabolic risk factors (eg, obesity, diabetes mellitus, dyslipidemia) and alternate causes for hepatic steatosis such as significant alcohol consumption or medications.**

**Screening for NAFLD in Primary Care, Diabetes, and Obesity Clinics**

It can be argued that there should be systematic screening for NAFLD, at least among higher-risk individuals with diabetes or obesity. For example, not only do patients with type 2 diabetes have higher prevalence of NAFLD, but the available evidence suggests higher prevalence of NASH and advanced stages of fibrosis among type 2 diabetes patients (72-74). However, there are significant gaps in our knowledge regarding the diagnosis, natural history, and treatment of NAFLD. A recent, cost-effective analysis using a Markov model suggested that screening for NASH in individuals with diabetes is not cost-effective at present, due to disutility associated with available treatment (75). Since liver biochemistries can be normal in patients with NAFLD, they may not be sufficiently sensitive to serve as screening tests, whereas liver ultrasound or...
transient elastography are potentially more sensitive, but their utility as screening tools is unproven. Some experts recently have called for “vigilance” for chronic liver disease in patients with type 2 diabetes, but not routine screening (76).

**Guidance Statements**

4. **Routine Screening for NAFLD in high-risk groups attending primary care, diabetes, or obesity clinics is not advised at this time due to uncertainties surrounding diagnostic tests and treatment options, along with lack of knowledge related to long-term benefits and cost-effectiveness of screening.**

5. **There should be a high index of suspicion for NAFLD and NASH in patients with type 2 diabetes. Clinical decision aids such as NAFLD Fibrosis Score or FIB4 or vibration controlled transient elastography (VCTE) can be used to identify those at low or high risk for advanced fibrosis (bridging fibrosis or cirrhosis).**

**Screening of Family Members**

Several studies suggest familial clustering of NAFLD (77-80). In a retrospective cohort study, Willner et al observed that 18% of patients with NASH have a similarly affected first-degree relative (80). In a familial aggregation study of overweight children with and without NAFLD, after adjusting for age, gender, race, and BMI, the heritability of magnetic resonance (MR)–measured liver fat fraction was 0.386, and fatty liver was present in 18% of family members of children with NAFLD in the absence of elevated alanine aminotransferase (ALT) and obesity (81). Data reporting the heritability of NAFLD have been highly variable, ranging from no detectable heritability, in a large Hungarian twin cohort, to nearly universal heritability, in a
study of obese adolescents (77,82,83). In an ongoing, well-characterized cohort of community-dwelling twins in California, using MRI to quantify steatosis and fibrosis, both steatosis and fibrosis correlated between monozygotic, but not dizygotic, twin pairs, and, after multivariable adjustment, the heritability of hepatic steatosis and fibrosis was 0.52 (95% CI, 0.31-0.73; \( p < 1.1 \times 10^{-11} \)) and 0.50 (95% CI, 0.28-0.72; \( p < 6.1 \times 10^{-1} \)), respectively (84).

**Guidance Statement**

6. Systematic screening of family members for NAFLD is not recommended currently.

**Initial Evaluation of the Patient with Suspected NAFLD**

The diagnosis of NAFLD requires that (a) there is hepatic steatosis by imaging or histology, (b) there is no significant alcohol consumption, (c) there are no competing etiologies for hepatic steatosis, and (d) there are no coexisting causes of chronic liver disease.

Common alternative causes of hepatic steatosis are significant alcohol consumption, hepatitis C, medications, parenteral nutrition, Wilson disease, and severe malnutrition (Table 1). When evaluating a patient with newly suspected NAFLD, it is important to exclude coexisting etiologies for chronic liver disease including hemochromatosis, autoimmune liver disease, chronic viral hepatitis, alpha-1 antitrypsin deficiency, Wilson disease, and drug induced liver injury.

Serologic evaluation can uncover laboratory abnormalities in patients with NAFLD that do not always reflect the presence of another liver disease. Two examples of this are elevated serum
ferritin and autoimmune antibodies. Mildly elevated serum ferritin is a common feature of NAFLD that does not necessarily indicate hepatic iron overload, though it can impact disease progression. While the data are somewhat conflicting, serum ferritin >1.5 upper limit of normal was associated with more advanced fibrosis in a retrospective cohort of 628 adults (85). If serum ferritin and transferrin saturation are elevated in a patient with suspected NAFLD, genetic hemochromatosis should be excluded. Mutations in the HFE gene occur with variable frequency in patients with NAFLD, and the clinical significance is unclear (86). Liver biopsy should be considered in the setting of high ferritin and a high iron saturation to determine the presence or extent of hepatic iron accumulation and to exclude significant hepatic injury in a patient with suspected NAFLD. Low titers of serum autoantibodies, particularly antismooth muscle and antinuclear antibodies, are common in patients with NAFLD and are generally considered to be an epiphenomenon of no clinical consequence, though they often require liver biopsy to exclude autoimmune disease. In a study of 864 well-characterized NAFLD subjects from the NASH Clinical Research Network, significant elevations in serum autoantibodies (anti-nuclear antibodies >1:160 or anti-smooth muscle antibodies >1:40) were present in 21% and were not associated with more advanced disease or atypical histologic features (87).

While other diseases are being excluded, history should be carefully taken for the presence of commonly associated comorbidities including central obesity, hypertension, dyslipidemia, diabetes or insulin resistance, hypothyroidism, polycystic ovary syndrome, and obstructive sleep apnea.

Guidance Statements

7. When evaluating a patient with suspected NAFLD, it is essential to exclude competing...
etologies for steatosis and coexisting common chronic liver disease.

8. In patients with suspected NAFLD, persistently high serum ferritin, and increased iron saturation, especially in the context of homozygote or heterozygote C282Y HFE mutation, a liver biopsy should be considered.

9. High serum titers of autoantibodies in association with other features suggestive of autoimmune liver disease (> 5 upper limit of normal aminotransferases, high globulins, or high total protein to albumin ratio) should prompt a work-up for autoimmune liver disease.

10. Initial evaluation of patients with suspected NAFLD should carefully consider the presence of commonly associated comorbidities such as obesity, dyslipidemia, insulin resistance or diabetes, hypothyroidism, polycystic ovary syndrome, and sleep apnea.

Noninvasive Assessment of Steatohepatitis and Advanced Fibrosis in NAFLD

The natural history of NAFLD is fairly dichotomous—NAFL is generally benign, whereas NASH can progress to cirrhosis, liver failure, and liver cancer. Liver biopsy is currently the most reliable approach for identifying the presence of steatohepatitis and fibrosis in patients with NAFLD, but it is generally acknowledged that biopsy is limited by cost, sampling error, and procedure-related morbidity and mortality. Serum aminotransferase levels and imaging tests such as ultrasound, computerized tomography, and MR do not reliably reflect the spectrum of liver histology in patients with NAFLD. Therefore, there has been significant interest in developing clinical prediction rules and noninvasive biomarkers for identifying steatohepatitis in patients with NAFLD, but their detailed discussion is beyond the scope of this practice guidance (47).

Noninvasive Quantification of Hepatic Steatosis in NAFLD

AASLD approved version submitted to HEPATOLOGY on June 28, 2017
Some studies suggest that degree of steatosis may predict the severity of histological features (eg, ballooning and steatohepatitis) (88) and the incidence and prevalence of diabetes in patients with NAFLD (89-91). MR imaging, either by spectroscopy (92) or by proton density fat fraction (93,94), is an excellent noninvasive modality for quantifying hepatic steatosis and is being widely used in NAFLD clinical trials (95). The use of transient elastography to obtain continuous attenuation parameters is a promising tool for quantifying hepatic fat in an ambulatory setting (74,96). However, the utility of noninvasively quantifying hepatic steatosis in patients with NAFLD in routine clinical care is limited.

**Noninvasive Prediction of Steatohepatitis in Patients with NAFLD**

The presence of metabolic syndrome is a strong predictor for the presence of steatohepatitis in patients with NAFLD (47,97-100). Although NAFLD is highly associated with components of metabolic syndrome, the presence of increasing an number of metabolic diseases such as insulin resistance, type 2 diabetes, hypertension dyslipidemia, and visceral obesity seems to increase the risk of progressive liver disease (16,18,41). Therefore, patients with NAFLD and multiple risk factors such as type 2 diabetes mellitus and hypertension are at the highest risk for adverse outcomes (20,101). Circulating levels of cytokeratin-18 fragments have been investigated extensively as novel biomarkers for the presence of steatohepatitis in patients with NAFLD (47,102,103). This test is currently not available in a clinical care setting.

**Noninvasive Assessment of Advanced Fibrosis in Patients with NAFLD**

The commonly investigated noninvasive tools for the presence of advanced fibrosis in NAFLD include clinical decision aids (eg, NAFLD fibrosis score, FIB-4 index, APRI), serum biomarkers
(Enhanced liver fibrosis panel, Fibrometer, FibroTest, Hepascore), or imaging (eg, transient elastography, MR elastography, acoustic radiation force impulse imaging, supersonic shear wave elastography) (104).

The NAFLD Fibrosis Score is based on 6 readily available variables (age, BMI, hyperglycemia, platelet count, albumin, aspartate aminotransferase to ALT ratio) and is calculated using the published formula (http://gihep.com/calculators/hepatology/nafld-fibrosis-score/). In a meta-analysis of 13 studies consisting of 3,064 patients, (47) the NAFLD Fibrosis Score had an area under the receiver operating curve (AUROC) of 0.85 for predicting advanced fibrosis (ie, bridging fibrosis with nodularity or cirrhosis). A score <61.455 had 90% sensitivity and 60% specificity to exclude advanced fibrosis, whereas a score >0.676 had 67% sensitivity and 97% specificity to identify the presence of advanced fibrosis. FIB-4 index (http://gihep.com/calculators/hepatology/fibrosis-4-score/) is an algorithm based on platelet count, age, AST, and ALT that offers dual cutoff values (patients with score < 1.45 are unlikely, whereas patients with score >3.25 are likely to have advanced fibrosis) (104). A recent study that compared various risk scores and elastography (MR as well as transient elastography) against liver histology showed that NAFLD Fibrosis Score and FIB-4 were (a) better than other indices such as BARD, APRI and AST/ALT ratio and (b) as good as MR elastography for predicting advanced fibrosis in patients with biopsy-proven NAFLD (105).

The Enhanced Liver Fibrosis (ELF) panel consists of plasma levels of 3 matrix turnover proteins (hyaluronic acid, TIMP-1, and PIIINP) had an AUROC of 0.90 with 80% sensitivity and 90% specificity for detecting advanced fibrosis (bridging fibrosis or cirrhosis) (106). This panel has
been recently approved for commercial use in Europe, but is not available for clinical use in the United States.

VCTE (Fibroscan®), which measures liver stiffness noninvasively, was recently approved by the United States Food and Drug Administration for use in both adults and children with liver diseases. Two recent studies investigated the performance of VCTE in patients with suspected NAFLD using an M probe. Tapper et al reported the performance of VCTE in 164 patients with biopsy-proven NAFLD (median BMI 32.2 kg/m²) from the United States (107,108). The optimal liver stiffness measurement cutoff for advanced fibrosis was 9.9 kPa with 95% sensitivity and 77% specificity. The AUROC for detecting advanced fibrosis was 0.93 (95% CI: 0.86-0.96).

Interestingly, in 27% of the participants the VCTE yielded unreliable results (107). Imajo et al reported the performance of VCTE an with M probe in 142 Japanese patients with biopsy-proven NAFLD (mean BMI 28.1 kg/m²) (108). The failure rate for VCTE in this cohort was 10.5%. The AUROC for VCTE for identifying advanced fibrosis (bridging fibrosis and cirrhosis) was 0.88 (95% CI: 0.79-0.97). The NASH Clinical Research Network (NASH CRN) recently reported its experience with VCTE in 511 patients with biopsy-proven NAFLD (mean BMI 33.6 kg/m²) across 8 clinical centers in the United States, using a machine guided protocol with either an M + or XL + probe (109). Failure rate for obtaining a reliable liver stiffness measurement was 2.6%. MR elastography (MRE) is excellent for identifying varying degrees of fibrosis in patients with NAFLD (110,111). In the study by Imajo et al, MRE performed better than VCTE for identifying fibrosis stage 2 or above, but they both performed equally well in identifying fibrosis stage 3 or above (ie, bridging fibrosis). AUROCs for TE and MRE were 0.88 and 0.89, respectively.
Recent genome-wide association studies have associated several genetic polymorphisms, notably PNPLA3 variants, with steatohepatitis and advanced fibrosis in patients with NAFLD (112-121). However, testing for these genetic variants in routine clinical care is currently not advocated.

**Guidance Statements**

11. In patients with NAFLD, the metabolic syndrome predicts the presence of steatohepatitis, and its presence can be used to target patients for a liver biopsy.

12. NAFLD Fibrosis Score or FIB-4 index are clinically useful tools for identifying NAFLD patients with higher likelihood of having bridging fibrosis (stage 3) or cirrhosis (stage 4).

13. VCTE or MRE are clinically useful tools for identifying advanced fibrosis in patients with NAFLD.

**When to Obtain a Liver Biopsy in Patients with NAFLD**

Liver biopsy remains the gold standard for characterizing liver histologic alterations in patients with NAFLD. However, biopsy is expensive, requires expertise for interpretation, and carries some morbidity and very rare mortality risk. Thus, it should be performed in those who would benefit the most from diagnosis, therapeutic guidance, and prognostic information.

**Guidance Statements**

14. Liver biopsy should be considered in patients with NAFLD who are at increased risk of having steatohepatitis and/or advanced fibrosis.

15. The presence of metabolic syndrome, NAFLD Fibrosis Score or FIB-4, or liver stiffness
measured by VCTE or MRE may be used for identifying patients who are at risk for steatohepatitis and/or advanced fibrosis.

16. Liver biopsy should be considered in patients with suspected NAFLD in whom competing etiologies for hepatic steatosis and the presence and/or severity of coexisting chronic liver diseases cannot be excluded without a liver biopsy.

**Histopathology of Adult NAFLD**

The histopathologic features of adult NAFLD are prototypic, regardless of underlying pathogenesis, with the exception of severe alcoholic hepatitis, which has lesions not shared by severe NASH (122). The goals for histopathologic evaluation of liver biopsy in a subject with suspected NAFLD include confirming or excluding the diagnosis and providing commentary on severity of the disease. It is currently the standard to report grade (necroinflammatory “activity”) separately from stage, which comments on location of abnormal collagen deposition and architectural remodeling, ie, “fibrosis.” The following diagnostic categories for NAFLD have been utilized by the NASH CRN: Not NAFLD (< 5% steatosis, by definition); NAFL, not NASH (≥5% steatosis, with or without lobular and portal inflammation); Borderline steatohepatitis, zone 3 or Borderline steatohepatitis, zone 1 (most, but not all criteria for steatohepatitis present, with accentuation of steatosis or injury in zone 3 or zone 1, respectively), and Definite steatohepatitis (all criteria present, including steatosis, hepatocellular ballooning, and lobular inflammation) (123). Any of these diagnostic categories, including Not NAFLD, may have no fibrosis or any amount of fibrosis up to cirrhosis. Specifically, stage 1 is zone 3 (perivenular),
perisinusoidal, or periportal fibrosis; stage 2 is both zone 3 and periportal fibrosis; stage 3 is bridging fibrosis with nodularity; stage 4 is cirrhosis.

Histopathologic features of NAFLD in children may differ from those in adult NAFLD, particularly in younger years: Steatosis may be more abundant, or accentuated in zone 1 hepatocytes, and inflammation and fibrosis may be concentrated in portal tracts initially. Ballooning is less frequent (124-126). Interested readers may refer to other recent publications for detailed description of pathological features of fatty liver disease in adults and children (126,127).

There are 2 systems for semiquantitative assessment of necroinflammatory lesions in NAFLD: NAFLD Activity Score (NAS) from the NASH CRN (128), and Steatosis Activity Fibrosis (SAF) from the European Fatty Liver Inhibition of Progression Consortium (129,130). Both utilize the lesions stated above, but exact criteria and stated goals for utilization differ. The former was developed as a method of comparing biopsies in clinical trials, but stands separately from a pattern-based diagnosis; the latter utilizes the score for diagnosis as well as for use in clinical trials. Clinicians and pathologists benefit from familiarity with understanding the details of these systems prior to implementation. Even though NAFLD and NASH result in diffuse parenchymal involvement, as with other forms of chronic liver injury, there is well-recognized regional variability. Sampling “error,” however, remains a concern for diagnosis (131) and for clinical trials with histologically-based entry criteria and outcomes. Approaches to lessen the effects of sampling error include large needle size (eg, 2-3 cm in length and 16 gauge) (132-134) and at least 1 core biopsy (133). The study by Vuppalanchi et al (133) noted that a diagnosis of definite NASH was more common with 2 cores, in biopsies ≥25 mm, and when a single expert pathologist read a biopsy twice.
Guidance Statements

17. Clinically useful pathology reporting should include a distinction between NAFL (steatosis), NAFL with inflammation, and NASH (steatosis with lobular and portal inflammation and hepatocellular ballooning). A comment on severity (mild, moderate, severe) may be useful. Specific scoring systems such as NAS (128) and/or Steatosis Activity Fibrosis (SAF) (128,129) may be used as deemed appropriate.

18. The presence or absence of fibrosis should be described. If present, a further statement related to location, amount, and parenchymal remodeling is warranted.

MANAGEMENT OF PATIENTS WITH NAFLD

WHOM TO TREAT: The management of NAFLD should consist of treating liver disease as well as the associated metabolic comorbidities such as obesity, hyperlipidemia, insulin resistance, and T2DM. As patients with NAFLD without steatohepatitis or any fibrosis have excellent prognosis from a liver standpoint, pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.

19. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.

Lifestyle Intervention

Lifestyle modification consisting of diet, exercise, and weight loss has been advocated to treat patients with NAFLD. The best data generated to date demonstrates that overall weight loss is the key to improvement in the histopathologic features of NASH. In a meta-analysis of 8
randomized controlled trials, 4 with post-treatment histology, those adults who were able to lose at least 5% of body weight had improvement in hepatic steatosis, while ≥7% body weight reduction was associated with NAS improvement (135). These data have been supported by a more recent 12-month prospective trial with paired liver biopsies in 261 patients (136). In this trial, a dose response curve was demonstrated wherein the greater the degree of weight loss, the more significant the improvement in histopathology such that ≥10% weight loss was associated with improvement in all features of NASH, including portal inflammation and fibrosis. However, it is important to note that those patients losing ≥5% body weight stabilized or improved fibrosis in 94% of the cases. Unfortunately, only 50% of patients were able to achieve at least a 7% weight loss at 12 months in this trial.

Compliance with a calorie-restricted diet over the long term is associated with mobilization of liver fat and improvement in cardiovascular risk (137). The specific macronutrient composition of the diet, over months to years, appears to be less relevant than the end result of sustained weight loss. Prospective trials comparing various macronutrient diets in NAFLD patients are limited by a lack of sufficient power as well as pre- and post-treatment histopathology. Data suggests, however, that decreasing caloric intake by at least 30% or by approximately 750-1000 kcal/day results in improvement in insulin resistance and hepatic steatosis (138,139). The Mediterranean diet (higher in monounsaturated fatty acids) has also been studied in comparison to a high-fat, low-carbohydrate diet for 6 weeks and, while there was no change in weight loss, MRI results showed significant improvement in steatosis in the Mediterranean diet group. Ultimately, rigorous, prospective, longer-term trials with histopathologic endpoints are required before recommendations related to specific macronutrient diets can be made.
The majority of NAFLD patients are engaged in minimal physical activity (140), and this has been associated with an increased risk of metabolic syndrome and NAFLD (141). Large, randomized controlled trials assessing the effect of exercise on histopathology in NASH are lacking; however, a recent meta-analysis showed an improvement in hepatic steatosis with exercise, but no improvement in alanine aminotransferase levels. The optimal duration and intensity of exercise remains undetermined. However, data suggest that patients who maintain physical activity more than 150 minutes/week or increase their activity level by more than 60 minutes/week have more pronounced decrement in serum aminotransferases, independent of weight loss (142). This is supported by a large Korean population study demonstrating that exercise frequency of ≥5 times/week, consisting of moderate exercise (carrying light loads, riding a bike at a steady pace, or playing tennis for at least 10 minutes), was associated with the greatest benefit in prevention of NAFLD development or improvement in patients that previously had NAFLD, independent of BMI over the 5-year follow-up (143). The effects of exercise on underlying NASH are less clear, but from a large, retrospective assessment of biopsy-proven NAFLD patients, moderate-intensity exercise (metabolic equivalents of 3-5.9) or total exercise per week was not associated with improvement in NASH severity or fibrosis. However, patients meeting vigorous (≥6 metabolic equivalents) activity recommendations did have improvement in NASH, although doubling of the vigorous activity recommendations was required to have a benefit on fibrosis (140).

Both diet and exercise counseling are often recommended for patients with NAFLD to achieve weight loss goals. Unfortunately, data evaluating the efficacy of combination diet and exercise on NAFLD are limited. When focusing on weight loss alone in a pooled analysis of 18 trials, combination diet plus exercise resulted in a 1.14 kg greater weight loss than diet alone (144).
Focusing on NAFLD, a systematic review of combined diet and aerobic exercise programs showed improvement in liver fat assessment and/or liver enzymes with 3 to 6 months of follow-up (145). In the largest paired biopsy study to date, 1 year of a calorically restricted diet (750 kcal/day) plus recommendations to walk 200 minutes/week resulted in a dose response relationship of weight loss to histopathologic improvement in inflammation, ballooning, and fibrosis (136).

**Guidance Statements**

20. Weight loss generally reduces hepatic steatosis, achieved either by hypocaloric diet alone or in conjunction with increased physical activity. A combination of a hypocaloric diet (daily reduction by 500-1000 kcal) and moderate intensity exercise is likely to provide the best likelihood of sustaining weight loss over time.

21. Weight loss of at least 3 to 5% of body weight appears necessary to improve steatosis, but a greater weight loss (7 to 10%) is needed to improve the majority of the histopathologic features of NASH, including fibrosis.

22. Exercise alone in adults with NAFLD may prevent or reduce hepatic steatosis, but its ability to improve other aspects of liver histology remains unknown.

**Insulin Sensitizers**

**Metformin**

Several studies investigated the effect of metformin on aminotransferases and/or liver histology in patients with NASH (146-156). Although several studies have shown an improvement in serum aminotransferases and insulin resistance, metformin does not significantly improve liver
histology. Two published meta-analyses conclude that metformin therapy did not improve liver histology in patients with NAFLD and NASH (157,158).

Guidance Statement

23. Metformin is not recommended for treating NASH in adult patients.

Thiazolidinediones

Thiazolidinediones are ligands for the nuclear transcription factor PPAR-γ with broad effects on glucose and lipid metabolism, as well as on vascular biology and inflammation (159). The ability of thiazolidinediones to reverse adipose tissue dysfunction and insulin resistance in obesity and T2DM have led to randomized controlled trials (RCTs) exploring their role in NASH (160). Studies with rosiglitazone reported an improvement in hepatic steatosis, but not of necroinflammation or fibrosis (161,162). Rosiglitazone is no longer available in most countries, and its prescribing remains severely restricted in the United States due to controversial findings of an increase in coronary events, although no firm association was found after an extensive review of all evidence by the Food and Drug Administration (163).

In an early proof-of-concept study, Belfort et al conducted an RCT of pioglitazone (45 mg/day) in 55 patients with NASH and prediabetes or T2DM (164). Treatment improved insulin sensitivity and aminotransferases, steatosis, inflammation, and ballooning. The NAS improved with pioglitazone in 73% compared to 24% of placebo-treated patients (P < 0.001) and there was a trend towards improvement in fibrosis among patients randomized to pioglitazone (P = 0.08). In a recent study, Cusi et al treated 101 patients with biopsy-
proven NASH having either prediabetes ($n = 49$) or T2DM ($n = 52$) with a hypocaloric diet (a 500 kcal/day deficit from weight-maintaining caloric intake) and pioglitazone, 45 mg/day, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment (165). The primary outcome was a reduction of at least 2 points in the NAS (in 2 different histologic categories) without worsening of fibrosis. In patients treated with pioglitazone, 58% achieved the primary outcome and 51% had resolution of NASH (both $P < 0.001$). Pioglitazone treatment also improved fibrosis ($P = 0.039$). Metabolic and histologic improvements continued over 36 months of therapy (165). Adverse events were overall no different between groups, but weight gain was greater with pioglitazone (2.5 kg vs placebo at 18 months; and a total of 3.0 kg over 36 months).

Pioglitazone is also of benefit in patients with NASH without diabetes. Aithal et al performed an RCT with either pioglitazone 30 mg/day or placebo for 12 months in 74 patients with NASH (166). While steatosis did not improve significantly compared to placebo, treatment did significantly ameliorate hepatocellular injury and fibrosis. In the Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis (PIVENS) trial, a large multicenter RCT in nondiabetic patients with NASH, 247 patients were randomized to pioglitazone (30 mg/day), vitamin E (800 IU/day), or placebo for 24 months (167). The primary endpoint was an improvement in NAS by $\geq 2$ points with at least 1-point improvement in hepatocellular ballooning and 1-point improvement in either the lobular inflammation or steatosis score, and no increase in the fibrosis score. This was achieved in 19% in the placebo group compared to 34% in the pioglitazone group ($P = 0.04$ vs placebo) and 43% in the vitamin E group ($P = 0.001$ vs placebo) (168). Because this study consisted of 2 primary
comparisons (pioglitazone vs placebo and vitamin E vs placebo), a P-value of 0.025 was considered to be significant a priori. Therefore, although there were histological benefits associated with pioglitazone, this study concluded that pioglitazone did not meet the primary end point. However, resolution of NASH, a key secondary end point, was achieved in a significantly higher number of patients receiving pioglitazone than receiving placebo (47% vs 21%, P < 0.001) (167). Vitamin E and pioglitazone were well tolerated and there were no differences in other adverse events.

Weight gain is the most common side effect associated with pioglitazone treatment, likely from improved adipose tissue insulin action and increased adipocyte triglyceride synthesis. It ranges from 2.5 kg to 4.7 kg in RCTs of 12- to 36-month duration (165-167). Bladder cancer has been a concern, with population-based studies reporting either positive or negative associations (169-171). However, Lewis et al followed 193,099 persons aged ≥40 years for up to 16 years and found no statistically significant association between bladder cancer risk and use of pioglitazone or increasing duration of therapy (172). Finally, bone loss may occur in women treated with thiazolidinediones (169).

Guidance Statements

24. Pioglitazone improves liver histology in patients with and without T2DM with biopsy-proven NASH. Therefore, it may be used to treat these patients. Risks and benefits should be discussed with each patient prior to starting therapy.

25. Until further data supports its safety and efficacy, pioglitazone should not be used to treat NAFLD without biopsy-proven NASH.
**Glucagon-Like Peptide-1 Analogues**

There has been an interest in investigating the role of glucagon-like peptide-1 as therapeutic agents in patients with NAFLD and NASH (173-177). In a recently published randomized placebo-controlled trial consisting of 52 patients with biopsy-proven NASH, liraglutide administered subcutaneously once daily for 48 weeks was associated with greater resolution of steatohepatitis and less progression of fibrosis (174). As expected, liraglutide was associated with greater weight loss but also gastrointestinal side effects.

**Guidance Statement**

26. **It is premature to consider glucagon-like peptide-1 agonists to specifically treat liver disease in patients with NAFLD or NASH.**

**Vitamin E**

Oxidative stress is considered a key mechanism of hepatocellular injury and disease progression in subjects with NASH. Vitamin E is an antioxidant and has been investigated as a treatment for NASH (178-182). Comparison between these trials is difficult due to varying criteria for entry into the study, different doses of vitamin E and unclear formulations of vitamin E used that could affect its bioavailability, the additional use of other antioxidants or other drugs, and limited histologic data to assess outcomes. Also, most studies were relatively under-powered and did not meet or publish CONSORT criteria for clinical trials. Despite these limitations, it can be summarized that (1) the use of vitamin E is associated with a decrease in aminotransferases in subjects with NASH, (2) studies in which histologic endpoints were evaluated indicate that vitamin E results in improvement in steatosis, inflammation, and ballooning and resolution of steatohepatitis in a proportion of nondiabetic adults with NASH, and (3) vitamin E did not have
an effect on hepatic fibrosis. In the PIVENS clinical trial (167), the pure form of rrr α-tocopherol was orally administered at a dose of 800 IU/day for 96 weeks. The primary endpoint was achieved in a significantly greater number of participants receiving vitamin E compared to placebo (42% vs 19%, P < 0.001, number needed to treat = 4.4). In the Treatment of Nonalcoholic Fatty Liver Disease in Children trial (TONIC), which tested vitamin E (800 IU/day) or metformin (500 mg twice daily) against placebo in children with biopsy-proven NAFLD, resolution of NASH was significantly greater in children treated with vitamin E than in children treated with placebo (58% vs 28%, P = 0.006) (183). Two recent meta-analyses reported significant histological benefits with vitamin E in patients with NASH (184,185).

There are also lingering concerns about the long-term safety of vitamin E. One meta-analysis suggested that doses of >800 IU/day were associated with increased all-cause mortality (186). However, this meta-analysis has been criticized because several studies with low mortality were excluded and concomitant vitamin A and other drug administration as well as common factors such as smoking were not considered. A subsequent analysis of these trials with the addition of more studies suggested the differences were driven by imbalance in males in the trials in question (187). A large meta-analysis that included 57 studies and 246,371 subjects followed from 1 to 10 years did not demonstrate a relationship between vitamin E supplementation and all-cause mortality (188). In a large RCT published in 2011, vitamin E administered at a dose of 400 IU/day was unexpectedly and unexplainably associated with a modest increase in the risk of prostate cancer (absolute increase of 1.6 per 1,000 person-years of vitamin E use) (189), and this risk may be modified by baseline selenium concentration (190) or genetic variants associated with vitamin metabolism (191).
Guidance Statements

27. Vitamin E (rrr α-tocopherol) administered at a daily dose of 800 IU/day improves liver histology in nondiabetic adults with biopsy-proven NASH and therefore may be considered for this patient population. Risks and benefits should be discussed with each patient prior to starting therapy.

28. Until further data supporting its effectiveness become available, vitamin E is not recommended to treat NASH in diabetic patients, NAFLD without liver biopsy, NASH cirrhosis, or cryptogenic cirrhosis.

Bariatric Surgery

NAFLD at all stages is more common in those who meet criteria for bariatric surgery. Nonsurgical weight loss is effective in improving all histologic features of NAFLD including fibrosis, though most patients had early stage fibrosis (136). However, sustained weight loss is difficult to achieve and harder yet to sustain. Bariatric surgery improves or eliminates comorbid disease in most patients and improves long-term survival and death from cardiovascular disease (CVD) and malignancy, the 2 most common causes of death in NAFLD(192-195). While there are no RCTs of bariatric surgery in NASH (and unlikely to be in the future), there are several retrospective and prospective cohort studies and 2 large single-center studies with follow-up liver biopsies. Mathurin et al prospectively correlated clinical and metabolic data with liver histology at time of surgery and 1 and 5 years after bariatric surgery in 381 adult patients with severe obesity (196). Gastric band, bilio-intestinal bypass, and gastric bypass were done in 56%, 23%, and 21%, respectively. Compared to baseline, there was a significant improvement in the prevalence and severity of steatosis and ballooning at 1 and 5 years following bariatric surgery.

AASLD approved version submitted to HEPATOLOGY on June 28, 2017
In patients with probable or definite NASH at baseline \((n = 99)\), there was a significant improvement in steatosis, ballooning, and NAS and resolution of probable or definite NASH at 1 and 5 years following bariatric surgery. Most histological benefits were evident at 1 year with no differences in liver histology between 1 and 5 years following bariatric surgery. Intriguingly, a minor but statistically significant increase in mean fibrosis score was noted at 5 years after the bariatric surgery (from \(0.27 \pm 0.55\) at baseline to \(0.36 \pm 0.59\), \(P = 0.001\)). Despite this increase, at 5 years, 96% of patients exhibited fibrosis score \(\leq 1\) and 0.5% had bridging fibrosis, indicating that there is no clinically significant worsening in fibrosis that can be attributed directly to the procedure. In a follow-up study focused on those with NASH at baseline undergoing bariatric surgery, Lassailly et al prospectively examined 109 patients with NASH at the time of bariatric surgery and performed follow-up biopsies 1 year later. Eighty-five percent of patients had NASH resolution (95% CI: 75.8%-92.2%). Importantly, in contrast to prior data, fibrosis improved at 1 year after surgery in 33% of patients (197). Furthermore, a meta-analysis of available data in 2015 also showed that the majority of patients undergoing bariatric surgery appear to improve or completely resolve the histopathologic features of steatosis, inflammation, and ballooning. Fibrosis also improved by a weighted mean decrease by 11.9% in the incidence of fibrosis (198).

The safety and efficacy of bariatric surgery in patients with NASH cirrhosis is not well established. An analysis performed from the Nationwide Inpatient Sample (1998-2007) estimated perioperative mortality and inpatient hospital stays for patients undergoing bariatric surgery with and without cirrhosis. Compared to those without cirrhosis (0.3%, \(n = 670,095\)), mortality was higher in those with compensated cirrhosis (0.9%, \(n = 3,888\)) and much higher in those with decompensated cirrhosis (16.3%, \(n = 62\)) (199). A recent systematic review of bariatric surgery in 122 patients with cirrhosis (97% Child’s A cirrhosis) described 1.6% early

AASLD approved version submitted to Hepatology on June 28, 2017

Hepatology

This article is protected by copyright. All rights reserved.
and 2.45% late, surgery-related mortality (200). Noteworthy is 0% mortality associated with surgery among 41 cirrhotic patients who had sleeve gastrectomy.

**Guidance Statements**

29. Foregut bariatric surgery can be considered in otherwise eligible obese individuals with NAFLD or NASH.

30. It is premature to consider foregut bariatric surgery as an established option to specifically treat NASH.

31. The type, safety, and efficacy of foregut bariatric surgery in otherwise eligible obese individuals with established cirrhosis due to NAFLD are not established. In otherwise eligible patients with compensated NASH or cryptogenic cirrhosis, foregut bariatric surgery may be considered on a case by case basis by an experienced bariatric surgery program.

**Ursodeoxycholic Acid, Omega-3 Fatty Acids, and Miscellaneous Agents**

Several studies (180,201-204) have investigated ursodeoxycholic acid (conventional and high doses) to improve aminotransferases and steatosis in patients with NAFLD and liver histology in patients with NASH. All but one study (203) have been proof-of-concept studies with small numbers of participants and/or surrogate endpoints. Notably, a single, large, multicenter RCT convincingly showed that ursodeoxycholic acid offers no histological benefit over placebo in patients with NASH (203). Omega-3 fatty acids, currently approved in the United States to treat hypertriglyceridemia, have been investigated to treat NAFLD both in animal models and in humans (205). In a review of the published literature in 2010, Masterton et al (206) found experimental evidence to support the use of omega-3 fatty acids in patients with NAFLD to improve liver disease, but the interpretation of human studies was limited by small sample size.
and methodological flaws. However, 2 recently reported studies failed to show convincing
erapeutic benefit for omega-3 fatty acids in patients with NAFLD or NASH (207,208). More
than a dozen other miscellaneous agents have been investigated in small, proof-of-concept
studies, and their detailed evaluation is beyond the scope of this guidance.

**Guidance Statements**

32. Ursodeoxycholic acid *is not recommended for the treatment of NAFLD or NASH.*

33. *Omega-3 fatty acids should not be used as a specific treatment of NAFLD or NASH, but they
may be considered to treat hypertriglyceridemia in patients with NAFLD.*

**Alcohol Use in Patients with NAFLD and NASH**

Heavy alcohol consumption is a risk factor for chronic liver disease and should be avoided by
patients with NAFLD and NASH. The National Institute on Alcohol Abuse and Alcoholism
defines heavy or at-risk drinking as more than 4 standard drinks on any day or more than 14
drinks per week in men or more than 3 drinks on any day or 7 drinks per week in women (209).
Although several cross-sectional studies (210-216) have suggested a beneficial effect of light
alcohol consumption (on average less than 1 drink per day) on the presence (defined either
biochemically or by imaging) and severity of NAFLD, a recent meta-regression analysis of
42,059 participants combined from 6 studies raised the possibility of potential confounding
caused by lower BMI among those who are moderate drinkers (217). There are no longitudinal
studies reporting the effect of ongoing alcohol consumption on disease severity or natural history
of NAFLD or NASH. The effects of light drinking on the cardiovascular system and cancer
risks, if any, have not been investigated in individuals with NAFLD.
Guidance Statements

34. Patients with NAFLD should not consume heavy amounts of alcohol.

35. There are insufficient data to make recommendations with regards to nonheavy consumption of alcohol by individuals with NAFLD.

Management of Cardiovascular Disease and Dyslipidemia

There is a strong association between NAFLD and increased risk of CVD events and mortality that withstands correction for traditional CVD risk factors (218,219). Debate remains over the causal relationship between NAFLD and CVD; however, NAFLD at minimum represents a risk marker, and thus, attention to and control of CVD risk factors is critical. Furthermore, there are many mechanistic links between NAFLD and various stages of the atherosclerotic process and cardiac structure and function. Some of these include but are not limited to endothelial dysfunction, atherogenic dyslipidemia and impaired cardiac mechanics (220).

Patients with NAFLD have a pro-atherogenic lipid profile characterized by high triglyceride, increased very low density lipoprotein and high apolipoprotein B to apolipoprotein A-1 ratio, as well as a higher concentration of small dense LDL coupled with low HDL concentration (221). These changes seem to be driven by hepatic lipid concentration and insulin resistance, predominately at the level of adipose tissue, rather than by the presence of NASH, per se (222,223). Although we have limited evidence of the long-term benefits of treating patients with NAFLD specifically, targeted treatment of atherogenic dyslipidemia in patients with diabetes or metabolic syndrome does reduce CVD and favorably impacts mortality. A recent post hoc analysis of the cardiovascular outcomes study, GREACE, observed that statins significantly
improved aminotransferases and cardiovascular outcomes in patients with elevated aminotransferases presumed due to NAFLD (224). Another post hoc analysis of the IDEAL trial suggested a benefit of high dose statins in those with baseline elevation in ALT compared to moderate intensity statins (225). Thus, it is reasonable to incorporate lipid-lowering therapy in patients with NAFLD who meet criteria based on current recommendations (226). While reluctance to use statins in patients with suspected or established chronic liver disease, including NAFLD and NASH, may persist, several studies have established the safety of statins in patients with liver disease regardless of baseline elevation in liver chemistries. Furthermore, the risk of statin induced hepatotoxicity is not higher in those with chronic liver disease (227,228).

Although elevated aminotransferases are not uncommon in patients receiving statins, serious liver injury from statins is quite rare in clinical practice.

Clinical trials of statins as treatment for NASH are limited and have shown inconsistent results, with liver enzymes improving modestly or not at all and variable effects on histology when this was assessed (229-232). One small RCT did not demonstrate a benefit of simvastatin in reducing liver enzymes or liver histology (233).

**Guidance Statements**

36. **Patients with NAFLD are at high risk for cardiovascular morbidity and mortality. Thus, aggressive modification of CVD risk factors should be considered in all patients with NAFLD.**

37. **Patients with NAFLD or NASH are not at higher risk for serious liver injury from statins. Thus, statins can be used to treat dyslipidemia in patients with NAFLD and NASH. While statins may be used in patients with NASH cirrhosis, they should be avoided in patients with**
Agents in Registration Trials

Currently, obeticholic acid (NCT02548351) and elafibranor (NCT02704403) are 2 compounds that are being tested in phase 3 registration trials. Obeticholic acid, a potent farnesoid X receptor agonist, administered at 25 mg per day dose improved steatohepatitis and fibrosis over a 72 week period in a large, multicenter, phase 2b clinical trial (234). In this study, OCA was associated with dyslipidemia and itching. This compound was recently approved by the United States Food and Drug Administration for treating patients with primary biliary cirrhosis who are unresponsive to ursodeoxycholic acid therapy in a dose up to 10 mg/day. Elafibranor (a dual PPARα/δ agonist) 120 mg/day, in a recently reported phase 2 study exhibited an efficacy signal for improving NASH without fibrosis worsening over a 12 month study period (235). While this treatment was associated with improved cardiometabolic profiles, there was a mild, reversible increase in serum creatinine.

Guidance Statement

38. Until further safety and efficacy data become available in patients with NASH, we recommend that obeticholic acid should not be used off-label to treat NASH.

NASH, Obesity and Liver Transplantation

Pre-Liver Transplant Considerations
NASH and cryptogenic cirrhosis are highly prevalent among patients awaiting liver transplantation, and, in fact, NASH is on a trajectory to become the most common indication for liver transplantation in the United States (45,67).

Higher BMI, common among patients with NASH, is associated with an increased risk of clinical decompensation while awaiting liver transplantation (236,237) and may present technical challenges to performing liver transplantation. Although an analysis of the United Network for Organ Sharing database reported a higher frequency of post-transplant complications and increased graft loss and mortality among patients with class III obesity (BMI > 40 kg/m²) at the time of transplant (238), when corrected for ascites, higher BMI does not appear to independently confer an increased risk of mortality or allograft failure (239,240). The effects of fluid retention on BMI and variability in the distribution of body fat reduce the utility of BMI as a sole factor in determining transplant candidacy. An upper limit of BMI that identifies candidates as technically inoperable or too high-risk for adverse post-transplant outcomes has not been identified for liver transplant recipients. In contrast, pre-transplant weight reduction and subsequently successful liver transplantation has been reported in a series of waitlisted patients with class III obesity (241). Substantial success has been reported in improving pre-transplant body habitus and weight through intensive diet and exercise in obese patients being considered for liver transplantation. The role of bariatric surgery as an adjunct to liver transplantation, particularly sleeve gastrectomy, which preserves absorptive dynamics of almost all medications as well as access to the lower esophagus, is under evaluation (241).

Obesity is strongly associated with sarcopenia, which has been consistently identified as an independent predictor of post-transplant mortality and graft loss (242-244). Because of the high prevalence of obesity and sarcopenia among patients with NASH and cryptogenic cirrhosis, a
multifaceted assessment of nutritional status is recommended. Preoperative nutritional status assessment with some combination of computed tomography (243, 245-247), dual energy X-ray absorptiometry (248), hand-grip strength (248), and triceps skinfold thickness (249) have all been reported to be useful in this setting.

As described previously, NASH is associated with a high frequency of cardiovascular disease (218, 250, 251). Noninvasive functional cardiac testing (eg, with dobutamine stress echocardiography) is recommended in patients with NASH cirrhosis, with progression to coronary angiography when noninvasive testing is abnormal or inconclusive (252). NASH is also associated with an increased prevalence of chronic kidney disease, and is, in fact, the most rapidly growing indication for simultaneous liver kidney transplantation in the United States (253). Because of the high prevalence of sarcopenia among patients with NASH, serum creatinine may overestimate glomerular filtration rate. Direct measures of glomerular filtration rate or determination of cystatin C (eg, with the creatinine-cystatin C equation) is more accurate than estimates of renal function that are derived from serum creatinine alone (254).

Post-Liver Transplant Considerations

Post-transplant outcomes are generally good following liver transplantation for NASH, with 1- and 3-year patient and graft survival rates that are comparable to other indications (45). The excellent 5-year graft survival suggests that recurrence of NASH is an uncommon cause of mortality and graft loss, at least in midterm (45). Some histological evidence of NAFLD is common following liver transplantation. Steatosis at or above grade 2 (34-66% by biopsy), for example, is seen in ~60% of recipients by the end of the second postoperative year, a rate that is higher than seen among patients undergoing liver transplantation for indications other than
NASH (255). NASH with progressive fibrosis, eg, METAVIR stage ≥2 (more than septal formation, thus bridging fibrosis and cirrhosis), is uncommon, occurring in ~5% of recipients by the fifth postoperative year (255,256). A recent single-center experience suggested higher incidence of advanced fibrosis (up to 27%), but this study suffers from modest sample size and selection bias (257).

In general, management recommendations for liver transplant recipients are similar to those for other patients with NASH. Ongoing attention to and assistance with achieving and maintaining a healthy weight and diet are important in the management of post-transplant NASH as weight gain is common following liver transplantation, exacerbated by immunosuppression and debility (258). Metabolic syndrome is very common in liver transplant recipients, particularly those with a history of NASH (259). There are some important pharmacological considerations that relate to the high prevalence of the metabolic syndrome among patients. Calcineurin inhibitors and corticosteroids exacerbate diabetes and impair insulin secretion (260,261).

**Guidance Statements**

39. *Patients with NASH cirrhosis have high prevalence of cardiovascular disease. Thus, careful attention should be paid to identifying cardiovascular disease, whether clinically apparent or occult, during the transplant evaluation process.*

**Miscellaneous Guidance Statements Pertinent to Clinical Practice**

40. *Patients with NASH cirrhosis should be screened for gastroesophageal varices according to the AASLD and American College of Gastroenterology practice guidelines (262).*
41. Patients with cirrhosis suspected due to NAFLD should be considered for HCC screening according to the AASLD practice guidelines (263).

42. Current evidence does not support routine screening and surveillance for HCC in patients with noncirrhotic NASH.

43. Current evidence does not support routinely repeating a liver biopsy in patients with NAFL or NASH, but this may be considered on a case by case basis.

Aspects of NAFLD Specific to Children and Adolescents

NAFLD in childhood may be due to more penetrant genetic risk or enhanced sensitivity to environmental provocation. Adults with onset of NAFLD in childhood may be most at risk for early or severe complications. The definitions of NAFLD and its subphenotypes in childhood are the same as in adults. Children with NAFLD are reported as early as 2 years and with NASH-related cirrhosis as early as age 8 years (124,264).

Prevalence and Risk Factors

Estimation of population prevalence of NAFLD in children presents difficulties for the same reasons detailed above in adults. Estimates vary based upon the type of test or imaging, the cut-points for detection, and the age, sex, race, and ethnicity of the geographic region sampled. A school-based study of obese children in Minnesota, California, Texas, and Louisiana, using abnormal serum ALT as a surrogate marker (>40U/L), found that 23% of 17-18 year olds had elevated unexplained ALT (264). An autopsy study using the “gold standard” of liver histology examined 742 children aged 2 to 19 years who died from unnatural causes. The estimated NAFLD prevalence was 9.6% when adjusted for age, gender, race, and ethnicity (124). A recent
meta-analysis demonstrated the pooled mean prevalence of NAFLD to be 7.6% in children from
general population studies and 34.2% in studies based on pediatric obesity clinics (265). This
meta-analysis highlights the higher prevalence of NAFLD in boys relative to girls, with
prevalence increasing incrementally with BMI z-score.

In a study of children with obesity with NAFLD and obstructive sleep apnea with chronic
intermittent hypoxemia, the severity of hypoxemia was found to be associated with histological
measures of NAFLD severity, particularly related to fibrosis stage (266). Histologic
abnormalities in children with NAFLD and normal or mildly elevated ALT levels may show
significant histological abnormalities, including advanced fibrosis in children with mildly
elevated ALT, so use of ALT alone may underestimate the extent of liver injury (267). In a
screening program of children with overweight and obesity referred from primary care,
evaluation of 347 children suspected of NAFLD on the basis of elevated ALT underwent
evaluation. NAFLD was diagnosed in 55% of these children, with liver diseases other than
NAFLD found in 18%; autoimmune hepatitis was the most common alternative diagnosis.
Advanced fibrosis (bridging fibrosis and cirrhosis) was present in 11% of the referred children
with NAFLD. Screening ALT with 2 times the upper limit of normal had a sensitivity of 57%
and a specificity of 71% (268).

Penetration of NAFLD has been demonstrated in family members of children with NAFLD (81).
The likelihood of first, second, and third degree relatives who exhibited abnormally high fat
fractions (by MRI estimation) relative to body mass index was much more highly correlated in
those related to a child with NAFLD than to those who were related to an age, gender, and BMI-matched child without NAFLD.

**Natural History of NAFLD in Children**

A retrospective single center report described the natural history of NAFLD in 66 children (269). Only 5 had serial biopsies, obtained for unspecified reasons over varying intervals, averaging 41 months between biopsies. Of these 5 children, 4 had progression of fibrosis. Four of the 5 underwent liver transplantation and 2 died of cirrhosis. The NASH Clinical Research Network reported the shorter-duration follow-up data on patients with NAFLD who received placebo along with standard-of-care lifestyle advice as part of the TONIC clinical trial. Forty-seven participants 8 to 17 years old at enrollment underwent 2 liver biopsies over 96 weeks. Remarkably, 5 developed type 2 diabetes during the study, which was related to baseline BMI z-score, HbA1c value, and ballooning score. Fibrosis stage remained the same or progressed in 60% of subjects, and those in whom fibrosis stage did not improve were more likely to be white, older, and with higher baseline NAS (270). More robust prospective data are needed on larger numbers of children to better detail the natural history of NAFLD in children.

**Screening for NAFLD in Children**

NAFLD is under-diagnosed in children due to lack of recognition, screening, or appreciation of associated complications by health care providers. One study showed that less than a third of children with obesity were screened for NAFLD with laboratory testing at clinic visits (271). Children may not be recognized as having obesity at visits, and age-appropriate norms for BMI may go unacknowledged. Abdominal adiposity may mask detection of hepatomegaly by
palpation during physician examination. As in adults, children with features of metabolic syndrome such as obesity, hypertension, insulin resistance, and dyslipidemia (81) are at higher risk for NAFLD, and particular histopathological features of NAFLD correlate with components of metabolic syndrome. Thus, identification of children at risk for NAFLD could occur in general health provider settings as well as in specialty clinics for nutrition, gastroenterology, hepatology, endocrinology, dyslipidemia, pulmonology, and bariatric surgery. Children may also exhibit NAFLD incidentally discovered while undergoing imaging, but there are no studies evaluating how to proceed with children identified in this fashion. Recently, the summary report of an expert committee suggested biannual screening for liver disease with serum ALT and AST starting at age 10 years in children with obesity and those with BMI in the 85th to 94th percentile with other risk factors (272).

**Diagnosis in Children**

Given the relatively early onset, caregivers must give additional consideration to the possibility of monogenic disorders that present as fatty liver disease in very young children. Considerations include inborn errors of fatty acid or carnitine metabolism, peroxisomal disorders, lysosomal storage disorders, celiac disease, Wilson disease, and cystic fibrosis (273). However, as in adults, positive serum autoantibodies are present in a significant population of children with biopsy-proven NAFLD, and on some occasions liver biopsy is required to discriminate between autoimmune hepatitis and NAFLD (81). Obviously, the confounding factor of alcohol use or abuse is much less common in children and standard questionnaires for quantifying alcohol intake are usually unnecessary. At the current time, no predictive panel of proteomic, lipidomic,
genomic, metabolomic, or clinical markers can reliably discriminate between NAFLD and NASH in children.

**Guidance Statements**

44. *Children with fatty liver who are very young or not overweight should be tested for monogenic causes of chronic liver disease such as fatty acid oxidation defects, lysosomal storage diseases, and peroxisomal disorders, in addition to those causes considered for adults (Table 1).*

45. *Low serum titers of autoantibodies are often present in children with NAFLD, but higher titers, particularly in association with higher serum aminotransferases, high globulins, or high total protein to albumin ratio should prompt a liver biopsy to exclude autoimmune hepatitis and related autoimmune disorders.*

46. *Due to a paucity of evidence, a formal recommendation cannot be made with regards to screening for NAFLD in children with overweight and obesity.*

**When to Obtain a Liver Biopsy for Suspected Pediatric NAFLD?**

The decision to perform a liver biopsy in a child to confirm the diagnosis of NAFLD must be weighed against the risks associated with biopsy and the likelihood that the result will impact management. In children with an uncertain diagnosis, biopsy may rule out potential drug hepatotoxicity, presence of more than one diagnosis, or lack of clarity due to presence of serum autoantibodies. When there is an interest in grading or staging NAFLD, instead of submitting all children with NAFLD to a liver biopsy, it would be optimal to identify those children who are more likely to have NASH, or to identify children with advanced fibrosis. Current radiologic
imaging technologies serving as surrogates for liver fibrosis on biopsy include, as in adults, assessments of transient elastography, MRE, and acoustic radiation force impulse imaging. At present, none of these techniques have been sufficiently validated to serve as sufficient replacements for tissue sampling (274). The continued paucity of natural history data confounds the decision to biopsy, as alteration of long-term outcomes with treatment based on severity of histology at baseline remains unknown.

As in adults, development of noninvasive biomarkers or imaging to identify those at risk for more rapid progression or severe disease onset is desirable. Particularly, accurate markers of cellular injury and fibrosis are needed. Two studies suggested that Enhanced Liver Fibrosis score can be used to accurately predict fibrosis in children with NAFLD, but these studies assayed a relatively small number of children, and fewer with advanced fibrosis (275,276). There is reported benefit in predicting fibrosis stage in pediatric patients with an AUROC of 0.92, though only 9 of the 76 subjects studied had bridging fibrosis or more (273). In one study consisting of 134 children with NAFLD, serum keratin 18 levels measured within 2 days of a liver biopsy showed a very strong correlation with steatosis, inflammation, hepatocellular ballooning, fibrosis, steatohepatitis, and the NAFLD activity score (277).

**Guidance Statements**

47. **Liver biopsy in children with suspected NAFLD should be performed in those in whom the diagnosis is unclear or in whom there is possibility of multiple diagnoses, or prior to initiating potentially hepatotoxic medical therapy.**

48. **A liver biopsy to establish a diagnosis of NASH should be obtained prior to starting children**
NAFLD Histology in Children

Histopathology of children with NAFLD can differ from that found in adults. In some instances, as in adults, children’s biopsies may show pronounced features of hepatocellular injury, lobular inflammation, and peri-sinusoidal fibrosis, but there is a unique pattern also recognized in children. This pattern is typified by either diffuse, marked, macrovesicular, hepatocellular steatosis or zone 1, periportal steatosis, portal inflammation, and portal fibrosis in the absence of ballooning (264,278,279). The etiopathogenesis, prognosis and response to treatment may be different in children with these findings.

Guidance Statement

49. Pathologists interpreting pediatric liver biopsies should recognize the unique pattern frequently found in children with NAFLD to appropriately characterize pediatric NAFLD.

Treatment in Children

Recommendations for pediatric treatment options are limited by a small number of randomized clinical trials and insufficient information on natural history to assess risk-benefit. The overall goal is to improve a child’s quality of life and reduce longer-term cardiovascular and liver morbidity and mortality. Given that early onset likely indicates higher likelihood of later complications, attempts should be made to identify children who will benefit from intervention.

Lifestyle modification

Because most pediatric NAFLD patients have obesity, addressing this is the first step.
A label study (280) in 84 Italian children with biopsy-proven NAFLD showed that >20% body weight reduction over 12 months resulted in improvement in serum ALT and steatosis by ultrasonography in most children with NAFLD. Reportedly, 94% of the 70 enrolled subjects were able to achieve this weight loss goal using caloric restriction and exercise advice. Because liver biopsies were not performed at the end of the study, the effect of lifestyle intervention on liver histology could not be determined. In another study, Nobili et al (281) randomized 53 children with biopsy-proven NAFLD to lifestyle modification plus antioxidant therapy or lifestyle modification and placebo. Antioxidant therapy did not improve liver histology, but children in both groups who had already reduced their weight through designated lifestyle changes showed significant improvement in steatosis, inflammation, ballooning, and the NAS.

In one study consisting of 51 children with severe obesity (BMI z-score >3.5) and NAFLD, intensive life style modification (either in an inpatient or ambulatory setting) offered sustained biochemical benefits in comparison to usual care (282).

No information exists on recommending any particular type of diet or exercise. Similarly, the degree of weight loss needed to improve various histological aspects of NASH in children is unknown. Further studies are needed to assess the efficacy of specific diets. Recommendations for overweight pediatric NAFLD patients should include consultation with a registered dietitian to assess quality of diet and measurement of caloric intake, adoption of American Heart Association dietary strategies, and regular aerobic exercise, progressing in difficulty as fitness allows (283).

**Pharmacotherapy**
As in adults, clinical trials for pediatric NAFLD generally targeted insulin resistance or oxidative stress. Open-label, proof-of-concept studies have utilized changes in serum ALT or liver brightness on ultrasound as endpoints (273). Agents evaluated thus far include metformin, vitamin E, ursodeoxycholic acid, and delayed-release cysteamine. A large multicenter RCT using change in histology as a secondary endpoint, called TONIC, compared the efficacy of vitamin E or metformin to placebo in 8 to 17 year olds with NAFLD (183). Although the primary outcome of sustained reduction of ALT was not different among the 3 groups, there were statistically significant improvements in NAS and resolution of NASH (P < 0.006) with vitamin E treatment compared to placebo over 96 weeks (183). In this study, metformin administered at a 500 mg, twice daily dose had no effect on liver biochemistry or liver histology. The results from another large multicenter RCT comparing the effect of delayed-release cysteamine to placebo were just reported (284). In this trial, the primary outcome, requiring reduction in NAS of 2 or more without worsening of fibrosis, was not achieved over the 52-week treatment interval. Interestingly, a secondary outcome comparing reduction in serum ALT on treatment to placebo did achieve significance. There has been some interest to evaluate omega-3 fatty acids to treat NAFLD in children. While a combination of eicosapentaenoic acid and docosahexaenoic acid failed to show significant therapeutic benefit in one study (285), docosahexaenoic acid administered at 250 mg/day for 6 months showed significant improvement in hepatic fat as well as cardiometabolic risk factors in another study (286).

**Guidance Statements**

50. **Intensive lifestyle modification improves aminotransferases and liver histology in**

51. **Children with NAFLD and thus should be the first line of treatment.**

52. **Metformin at 500 mg twice daily offers no benefit to children with NAFLD and thus should**
not be prescribed to specifically treat NAFLD or NASH. The effect of metformin administered at a higher dose is not known.

Vitamin E (RRR α-tocopherol) 800 IU/day offers histological benefits to some children with biopsy-proven NASH. Long-term safety of high-dose vitamin E in children is unknown. Vitamin E may be used to treat NASH in children, but risks and benefits should be discussed with each patient.
Table 1: Common Causes of Secondary Hepatic Steatosis

<table>
<thead>
<tr>
<th>Macrovesicular steatosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Excessive alcohol consumption</td>
</tr>
<tr>
<td>- Hepatitis C (genotype 3)</td>
</tr>
<tr>
<td>- Wilson disease</td>
</tr>
<tr>
<td>- Lipodystrophy</td>
</tr>
<tr>
<td>- Starvation</td>
</tr>
<tr>
<td>- Parenteral nutrition</td>
</tr>
<tr>
<td>- Abetalipoproteinemia</td>
</tr>
<tr>
<td>- Medications (eg, mipomersen, lomitapide, amiodarone, methotrexate, tamoxifen, corticosteroids)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Microvesicular steatosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Reye syndrome</td>
</tr>
<tr>
<td>- Medications (valproate, anti-retroviral medicines)</td>
</tr>
<tr>
<td>- Acute fatty liver of pregnancy</td>
</tr>
<tr>
<td>- HELLP syndrome</td>
</tr>
<tr>
<td>- Inborn errors of metabolism (eg, lecithin-cholesterol acyltransferase deficiency, cholesterol ester storage disease, Wolman disease)</td>
</tr>
</tbody>
</table>

AASLD approved version submitted to HEPATOLOGY on June 28, 2017

This article is protected by copyright. All rights reserved.
Table 2: Nonalcoholic Fatty Liver Disease and Related Definitions

<table>
<thead>
<tr>
<th>Nonalcoholic Fatty Liver Disease (NAFLD)</th>
<th>Encompasses the entire spectrum of fatty liver disease in individuals without significant alcohol consumption, ranging from fatty liver to steatohepatitis to cirrhosis.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonalcoholic Fatty Liver (NAFL)</td>
<td>Presence of $&gt;5%$ hepatic steatosis without evidence of hepatocellular injury in the form of ballooning of the hepatocytes or evidence of fibrosis. The risk of progression to cirrhosis and liver failure is considered minimal.</td>
</tr>
<tr>
<td>Nonalcoholic Steatohepatitis (NASH)</td>
<td>Presence of $&gt;5%$ hepatic steatosis with inflammation and hepatocyte injury (ballooning) with or without fibrosis. This can progress to cirrhosis, liver failure, and rarely liver cancer.</td>
</tr>
<tr>
<td>NASH Cirrhosis</td>
<td>Presence of cirrhosis with current or previous histological evidence of steatosis or steatohepatitis</td>
</tr>
<tr>
<td>Cryptogenic Cirrhosis</td>
<td>Presence of cirrhosis with no obvious etiology. Patients with cryptogenic cirrhosis are heavily enriched with metabolic risk factors such as obesity and metabolic syndrome.</td>
</tr>
<tr>
<td>NAFLD Activity Score (NAS)</td>
<td>An unweighted composite of steatosis, lobular inflammation, and ballooning scores. NAS is a useful tool to measure changes in liver histology in patients with NAFLD in clinical trials. Fibrosis is scored separately (126).</td>
</tr>
<tr>
<td>Steatosis Activity Fibrosis (SAF) Score</td>
<td>A semiquantitative score consisting of steatosis amount, activity (lobular inflammation plus ballooning), and fibrosis (130).</td>
</tr>
</tbody>
</table>
**Table 3:** Risk Factors Associated with NAFLD

<table>
<thead>
<tr>
<th>Common conditions with established association</th>
<th>Other conditions associated with NAFLD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obesity</td>
<td>Hypothyroidism</td>
</tr>
<tr>
<td>Type 2 diabetes mellitus</td>
<td>Obstructive sleep apnea</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>Hypopituitarism</td>
</tr>
<tr>
<td>Metabolic syndrome**</td>
<td>Hypogonadism</td>
</tr>
<tr>
<td>Polycystic ovary syndrome</td>
<td>Pancreato-duodenal resection</td>
</tr>
<tr>
<td></td>
<td>Psoriasis</td>
</tr>
</tbody>
</table>

**The Adult Treatment Panel III clinical definition of the metabolic syndrome requires the presence of 3 or more of the following features: (1) waist circumference greater than 102 cm in men or greater than 88 cm in women, (2) triglyceride level 150 mg/dL or greater, (3) HDL cholesterol level less than 40 mg/dL in men and less than 50 mg/dL in women, (4) systolic blood pressure 130 mm Hg or greater or diastolic pressure 85 mm Hg or greater, and (5) fasting plasma glucose level 110 mg/dL or greater (287).**
Supplemental Table 1: Summary of Guidance Statements

**Alcohol Consumption and Definition of NAFLD**

1. **Ongoing or recent alcohol consumption > 21 standard drinks on average per week in men and > 14 standard drinks on average per week in women is a reasonable threshold for significant alcohol consumption when evaluating patients with suspected NAFLD.**

**Incidentally Discovered Hepatic Steatosis**

2. **Patients with unsuspected hepatic steatosis detected on imaging who have symptoms or signs attributable to liver disease or have abnormal liver chemistries should be evaluated as though they have suspected NAFLD and worked up accordingly.**

3. **Patients with incidental hepatic steatosis detected on imaging who lack any liver-related symptoms or signs and have normal liver biochemistries should be assessed for metabolic risk factors (eg, obesity, diabetes mellitus, dyslipidemia) and alternate causes for hepatic steatosis such as significant alcohol consumption or medications.**

**Screening for NAFLD in Primary Care, Diabetes, and Obesity Clinics**

4. **Routine Screening for NAFLD in high-risk groups attending primary care, diabetes, or obesity clinics is not advised at this time due to uncertainties surrounding diagnostic tests and treatment options, along with lack of knowledge related to long-term benefits and cost-effectiveness of screening.**

5. **There should be a high index of suspicion for NAFLD and NASH in patients with type 2 diabetes. Clinical decision aids such as NAFLD Fibrosis Score or FIB4 or vibration controlled transient elastography (VCTE) can be used to identify those at low or high risk for advanced fibrosis (bridging fibrosis or cirrhosis).**
Screening of Family Members

6. Systematic screening of family members for NAFLD is not recommended currently.

Initial Evaluation of the Patient with Suspected NAFLD

7. When evaluating a patient with suspected NAFLD, it is essential to exclude competing etiologies for steatosis and coexisting common chronic liver disease.

8. In patients with suspected NAFLD, persistently high serum ferritin, and increased iron saturation, especially in the context of homozygote or heterozygote C282Y HFE mutation, a liver biopsy should be considered.

9. High serum titers of autoantibodies in association with other features suggestive of autoimmune liver disease (> 5 upper limit of normal aminotransferases, high globulins, or high total protein to albumin ratio) should prompt a work-up for autoimmune liver disease.

10. Initial evaluation of patients with suspected NAFLD should carefully consider the presence of commonly associated comorbidities such as obesity, dyslipidemia, insulin resistance or diabetes, hypothyroidism, polycystic ovary syndrome, and sleep apnea.

Noninvasive Assessment of Steatohepatitis and Advanced Fibrosis in NAFLD

11. In patients with NAFLD, the metabolic syndrome predicts the presence of steatohepatitis, and its presence can be used to target patients for a liver biopsy.

12. NAFLD Fibrosis Score or FIB-4 index are clinically useful tools for identifying NAFLD patients with higher likelihood of having bridging fibrosis (stage 3) or cirrhosis (stage 4).

13. VCTE or MRE are clinically useful tools for identifying advanced fibrosis in patients with NAFLD.
When to Obtain a Liver Biopsy in Patients with NAFLD

14. Liver biopsy should be considered in patients with NAFLD who are at increased risk of having steatohepatitis and/or advanced fibrosis.

15. The presence of metabolic syndrome, NAFLD Fibrosis Score or FIB-4, or liver stiffness measured by VCTE or MRE may be used for identifying patients who are at risk for steatohepatitis and/or advanced fibrosis.

16. Liver biopsy should be considered in patients with suspected NAFLD in whom competing etiologies for hepatic steatosis and the presence and/or severity of coexisting chronic liver diseases cannot be excluded without a liver biopsy.

Histopathology of Adult NAFLD

17. Clinically useful pathology reporting should include a distinction between NAFL (steatosis), NAFL with inflammation, and NASH (steatosis with lobular and portal inflammation and hepatocellular ballooning). A comment on severity (mild, moderate, severe) may be useful. Specific scoring systems such as NAS (128) and/or Steatosis Activity Fibrosis (SAF) (128,129) may be used as deemed appropriate.

18. The presence or absence of fibrosis should be described. If present, a further statement related to location, amount, and parenchymal remodeling is warranted.

Management Of Patients With NAFLD

19. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.
### Lifestyle Intervention

20. **Weight loss generally reduces hepatic steatosis, achieved either by hypocaloric diet alone or in conjunction with increased physical activity. A combination of a hypocaloric diet (daily reduction by 500-1000 kcal) and moderate intensity exercise is likely to provide the best likelihood of sustaining weight loss over time.**

21. **Weight loss of at least 3 to 5% of body weight appears necessary to improve steatosis, but a greater weight loss (7 to 10%) is needed to improve the majority of the histopathologic features of NASH, including fibrosis.**

22. **Exercise alone in adults with NAFLD may prevent or reduce hepatic steatosis, but its ability to improve other aspects of liver histology remains unknown.**

### Insulin Sensitizers

23. **Metformin is not recommended for treating NASH in adult patients.**

24. **Pioglitazone improves liver histology in patients with and without T2DM with biopsy-proven NASH. Therefore, it may be used to treat these patients. Risks and benefits should be discussed with each patient prior to starting therapy.**

25. **Until further data supports its safety and efficacy, pioglitazone should not be used to treat NAFLD without biopsy-proven NASH.**

26. **It is premature to consider glucagon-like peptide-1 agonists to specifically treat liver disease in patients with NAFLD or NASH.**

### Vitamin E

27. **Vitamin E (**rrr α-tocopherol**) administered at a daily dose of 800 IU/day improves liver histology in nondiabetic adults with biopsy-proven NASH and therefore may be considered for this patient population. Risks and benefits should be discussed with each patient.**
28. Until further data supporting its effectiveness become available, vitamin E is not recommended to treat NASH in diabetic patients, NAFLD without liver biopsy, NASH cirrhosis, or cryptogenic cirrhosis.

**Bariatric Surgery**

29. Foregut bariatric surgery can be considered in otherwise eligible obese individuals with NAFLD or NASH.

30. It is premature to consider foregut bariatric surgery as an established option to specifically treat NASH.

31. The type, safety, and efficacy of foregut bariatric surgery in otherwise eligible obese individuals with established cirrhosis due to NAFLD are not established. In otherwise eligible patients with compensated NASH or cryptogenic cirrhosis, foregut bariatric surgery may be considered on a case by case basis by an experienced bariatric surgery program.

**Ursodeoxycholic Acid, Omega-3 Fatty Acids, and Miscellaneous Agents**

32. Ursodeoxycholic acid is not recommended for the treatment of NAFLD or NASH.

33. Omega-3 fatty acids should not be used as a specific treatment of NAFLD or NASH, but they may be considered to treat hypertriglyceridemia in patients with NAFLD.

**Alcohol Use in Patients with NAFLD and NASH**

34. Patients with NAFLD should not consume heavy amounts of alcohol.

35. There are insufficient data to make recommendations with regards to nonheavy consumption of alcohol by individuals with NAFLD.

**Management of Cardiovascular Disease and Dyslipidemia**

36. Patients with NAFLD are at high risk for cardiovascular morbidity and mortality. Thus,
aggressive modification of CVD risk factors should be considered in all patients with NAFLD.

37. Patients with NAFLD or NASH are not at higher risk for serious liver injury from statins. Thus, statins can be used to treat dyslipidemia in patients with NAFLD and NASH. While statins may be used in patients with NASH cirrhosis, they should be avoided in patients with decompensated cirrhosis.

Agents in Registration Trials

38. Until further safety and efficacy data become available in patients with NASH, we recommend that obeticholic acid should not be used off-label to treat NASH.

NASH, Obesity and Liver Transplantation

39. Patients with NASH cirrhosis have high prevalence of cardiovascular disease. Thus, careful attention should be paid to identifying cardiovascular disease, whether clinically apparent or occult, during the transplant evaluation process.

Miscellaneous Guidance Statements Pertinent to Clinical Practice

40. Patients with NASH cirrhosis should be screened for gastroesophageal varices according to the AASLD[ and American College of Gastroenterology practice guidelines (262).

41. Patients with cirrhosis suspected due to NAFLD should be considered for HCC screening according to the AASLD practice guidelines (263).

42. Current evidence does not support routine screening and surveillance for HCC in patients with noncirrhotic NASH.

43. Current evidence does not support routinely repeating a liver biopsy in patients with NAFL or NASH, but this may be considered on a case by case basis.
Aspects of NAFLD Specific to Children and Adolescents

44. Children with fatty liver who are very young or not overweight should be tested for monogenic causes of chronic liver disease such as fatty acid oxidation defects, lysosomal storage diseases, and peroxisomal disorders, in addition to those causes considered for adults (Table 1).

45. Low serum titers of autoantibodies are often present in children with NAFLD, but higher titers, particularly in association with higher serum aminotransferases, high globulins, or high total protein to albumin ratio should prompt a liver biopsy to exclude autoimmune hepatitis and related autoimmune disorders.

46. Due to a paucity of evidence, a formal recommendation cannot be made with regards to screening for NAFLD in children with overweight and obesity.

When to Obtain a Liver Biopsy for Suspected Pediatric NAFLD?

47. Liver biopsy in children with suspected NAFLD should be performed in those in whom the diagnosis is unclear or in whom there is possibility of multiple diagnoses, or prior to initiating potentially hepatotoxic medical therapy.

48. A liver biopsy to establish a diagnosis of NASH should be obtained prior to starting children on pharmacologic therapy for NASH.

NAFLD Histology in Children

49. Pathologists interpreting pediatric liver biopsies should recognize the unique pattern frequently found in children with NAFLD to appropriately characterize pediatric NAFLD.

Treatment in Children

50. Intensive lifestyle modification improves aminotransferases and liver histology in

51. Children with NAFLD and thus should be the first line of treatment.
52. Metformin at 500 mg twice daily offers no benefit to children with NAFLD and thus should not be prescribed to specifically treat NAFLD or NASH. The effect of metformin administered at a higher dose is not known.

53. Vitamin E (RRR α-tocopherol) 800 IU/day offers histological benefits to some children with biopsy-proven NASH. Long-term safety of high-dose vitamin E in children is unknown. Vitamin E may be used to treat NASH in children, but risks and benefits should be discussed with each patient.
References


5. Hannah WN, Harrison SA. Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2016;


AASLD approved version submitted to HEPATOLOGY on June 28, 2017
10. Sung K-C, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol. 2014;60:1040–1045.


AASLD approved version submitted to HEPATOLOGY on June 28, 2017


101. Younossi ZM, Ogtonsuren M, Venkatesan C, Mishra A. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism. 2013;62:352–360.


AASLD approved version submitted to HEPATOLOGY on June 28, 2017


130. Bedossa P, the FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565–575.


AASLD approved version submitted to HEPATOLOGY on June 28, 2017

Hepatology

This article is protected by copyright. All rights reserved.


nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol. 2010;45:750–757.


AASLD approved version submitted to HEPATOLOGY on June 28, 2017

Hepatology

This article is protected by copyright. All rights reserved.


